Drugs - Xagena.net - Update in Medicine

Search results for "Dabrafenib"

Long-term survival benefit for metastatic melanoma patients treated with Dabrafenib plus Trametinib

The results from COMBI-d and COMBI-v clinical trials were presented at the 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting and published simultaneously in The New England Journal of ... read article

Positive CHMP opinion for Tafinlar in combination with Mekinist in BRAF-positive non-small cell lung cancer patients

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending approval of Tafinlar ( Dabrafenib ) in combination with ... read article

Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, CHMP positive opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Tramet ... read article

EMA: GSK has withdrawn combined use of Trametinib and Dabrafenib in unresectable or metastatic melanoma

GlaxoSmithKline ( GSK ) has announced that it has withdrawn its Marketing Authorisation Application ( MAA ) to the European Medicines Agency ( EMA ) for the use of Mekinist ( Trametinib ) in combinati ... read article

Dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation

The FDA ( Food and Drug Administration ) has approved Dabrafenib ( Tafinlar capsule ), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article